- ImmunoPrecise Antibodies Ltd. (IPA, Financial) delivers groundbreaking epitope mapping results with its LENSai™ platform.
- The AI-powered platform achieves x-ray-level precision in hours, comparable to traditional gold-standard methods.
- LENSai™ reduces costly and time-consuming lab work, offering a scalable approach to antibody discovery.
ImmunoPrecise Antibodies Ltd. (IPA) (IPA), a leader in AI-driven biotherapeutics, has announced impressive benchmarking results from its LENSai™ platform. This latest development in the field of computational biology showcases the platform's ability to match the precision of x-ray crystallography, the industry’s most accurate but slowest and most expensive method, by using sequence data alone.
Traditionally, epitope mapping, a critical step in antibody development, demands extensive lab work and the use of scarce protein samples. However, LENSai™ transforms this process by generating high-resolution insights quickly and cost-effectively. Tested across five known antibody-antigen pairs, the platform's predictive accuracy (AUC 0.79–0.89) was found to be on par or superior to established methods, while significantly reducing the turnaround time from weeks to just hours.
Dr. Jennifer Bath, CEO of IPA, underscores the impact of LENSai™ in addressing the high failure rates and expenses in the drug development pipeline: "In an industry where over 95% of drug candidates fail before reaching the clinic, accelerating decisions earlier in the discovery pipeline isn’t a luxury—it’s a necessity." The platform is positioned to play a critical role in the evolving landscape of biotherapeutic discovery, aligning with new regulatory practices, including the FDA's move to eliminate animal testing requirements for biologics.
LENSai™ continues to evolve, building on prior innovations in in silico antibody engineering and multi-omics integration. This advancement not only reduces the cost and risk associated with physical materials but also provides pharmaceutical and biotech partners with validated, scalable solutions that accelerate the therapeutic development process.
